CFTR transcripts have been qualitatively and quantitatively analysed in nasal epithelial and vas deferens cells by means of reverse transcription PCR. Alternative splicing of exon 9, which is known to occur in nasal epithelial cells, also occurred in vas deferens cells. The extent of this alternative splicing was determined by the allele present at the Tn locus at the end of intron 8 of the CFTR gene. However, the proportion of transcripts lacking exon 9 sequences was increased in vas deferens cells compared with nasal epithelial cells, independent of the Tn genotype. We postulate that this tissue specific difference in the proportion of CFTR transcripts lacking exon 9 sequences could contribute to the tissue specific disease phenotype observed in individuals with congenital bilateral absence of the vas deferens.
INTRODUCTION
Congenital bilateral absence of the vas deferens (CBAVD) accounts for at least 6% of the cases of obstructive azoospermia and is responsible for 1-2% of the cases of infertility in men (1, 2) . CBAVD is also present in nearly all male cystic fibrosis (CF) patients (3) . Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene (4) , which encodes a cAMP-regulated chloride channel (5) , are responsible for CF (6, 7) and for the majority of the CBAVD cases (8) (9) (10) (11) . Patients with the classic form of CF have severe mutations in each copy of the CFTR gene. Patients with a less severe phenotype, such as CF patients with mild lung disease and normal pancreatic function and the majority of CBAVD individuals, have a severe mutation in one copy of CFTR and a mild mutation in the other, or mild mutations in both copies. In contrast with CF patients, CBAVD individuals have no, or only minor, pulmonary symptoms (9, 12) . In CBAVD individuals, an impaired chloride conductance is observed across nasal epithelium which is nevertheless different from that found in CF patients. However, normal sodium transport across nasal epithelium is found in CBAVD men, in contrast with CF patients who exhibit increased sodium absorption (13) .
At the polymorphic Tn locus at the end of intron 8, three alleles can be found depending on the number of thymidines present at this site (14) . This number of thymidines determines the efficiency by which the intron 8 splice acceptor site is used (14) (15) (16) . The T5 allele will result in the most inefficient use of this splice acceptor site. The majority of CFTR transcripts from a T5 allele will therefore lack exon 9 sequences (14-16). Such exon 9-CFTR transcripts are known to be translated into CFTR proteins that will not mature, and will therefore not function as chloride channels in the apical membrane of epithelial cells (17, 18) . Among CBAVD patients, the frequency of this T5 allele is 4-to 6-fold higher than in the control population (9) (10) (11) . The T5 mutation is therefore classified as a CBAVD mutation, although with incomplete penetrance since identical genotypes can be found both in CBAVD and in non-CBAVD individuals (9, 10) .
The effect of the Tn locus on exon 9 alternative splicing has so far only been investigated in nasal/bronchial epithelial cells and white blood cells (14) (15) (16) , but never in vas deferens tissue. Given the fact that the T5 allele turns out to be the most frequent CBAVD mutation, we therefore investigated exon 9 alternative splicing in vas deferens tissue.
RESULTS
A total of 47 vas deferens biopsies were obtained. Genomic analysis of the polymorphic Tn locus revealed allele frequencies of 1.1, 88.3 and 10.6% for the T5, T7 and T9 alleles, respectively. The frequency of the T5 allele observed in CFTR genes derived from healthy men who underwent a vasectomy was lower than that found in CBAVD individuals (20.1-27.1%; 9-11) and in control CFTR genes derived from parents of CF patients (5.7%; 19,20) . In agreement with the fact that T5 is a CBAVD mutation, though with incomplete penetrance, the proportion of T5 alleles among vas deferens biopsies obtained from healthy fertile men is here found to be decreased.
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Initially, all biopsies obtained were analysed. Later, given the fact that most individuals were homozygous for the T7 allele, only biopsies that were obtained from individuals heterozygous for the T7 allele, or that did not carry the T7 allele at all, were analysed. In total, CFTR transcripts from 24 biopsies were qualitatively and quantitatively analysed by means of reverse transcription PCR. Alternative splicing of exon 9 was observed in all investigated samples. The mean proportion, and their 95% confidence intervals, of exon 9-transcripts for the observed genotypes were: T9/T9, 0.04 ± 0.02; T9/T7, 0.16 ± 0.01; T7/T7, 0.24 ± 0.01; and T7/T5, 0.52 ± 0.05 (Table 1) . Analysis of variance revealed that the means from the four groups were significantly different from each other (P < 0.001). Subsequent post-hoc pairwise comparison tests according to Bonferroni showed that the means for all tested genotypes were significantly different from each other (P < 0.003).
We next investigated the proportion of exon9-transcripts found in vas deferens tissue compared with the proportion found in nasal epithelial cells. It should be noted, however, that all nasal biopsies were obtained from other individuals than those who provided vas deferens biopsies. For the nasal epithelial cells, fresh biopsies and/or cultured cells from the biopsies were examined. Indeed, in contrast with vas deferens tissue, nasal epithelial cells are in direct contact with the environment and could therefore be more prone to environmental factors (such as infections) which influence CFTR expression. The controlled conditions in which nasal epithelial cells are cultured from nasal biopsies could reduce, or normalize, possible environmental influences that might otherwise be responsible for differences in the nature of transcripts between different nasal biopsies.
For three individuals, both fresh and cultured nasal epithelial cells were analysed ( Table 2 ). In one sample (sample 2), a slightly higher proportion of exon9-CFTR transcripts was found in fresh nasal epithelial cells compared with cultured ones. No significant differences were found in the two other samples.
DISCUSSION
Qualitative and quantitative CFTR transcript analysis of fresh and cultured nasal epithelial cells revealed, in agreement with previous reports (14-16), an inverse relationship between the number of thymidines at the Tn locus in intron 8 of the CFTR gene, and the amount of exon9-transcripts. The mean proportion of exon9-transcripts for the observed genotypes were: T9/T9, 0.01 ± 0.00; T9/T7, 0.06 ± 0.01; T7/T7, 0.14 ± 0.01; and T7/T5, 0.46 ± 0.03. This is considerably lower than previously described (14) (15) (16) . For the respective genotypes, the following proportions of exon9-transcripts were observed by Chu et al. (16) : T9/T9, 0.13 ± 0.05; T9/T7, 0.17 ± 0.02; T7/T7, 0.25 ± 0.02; and T7/T5, 0.66 ± 0.02. A possible explanation for these differences could be the design of the quantitative experiments in these two studies. In contrast with Chu et al. (16) , we only performed one round of PCR instead of two. Secondly, we performed a sensitive direct visualisation of fluorescent labelled PCR products instead of an indirect visualisation by means of hybridisation of the PCR products to a probe and subsequent densitometric scanning. In our protocol, the number of manipulations is reduced to a minimum. Our finding of a lower proportion of exon9-transcripts in nasal epithelial cells could be important. Indeed, in previous studies it was found that up to 92% of the CFTR transcripts in healthy individuals homozygous for the T5 allele will lack exon 9 sequences (15). Given this observation, and the fact that normal human nasal, tracheal and bronchial epithelial cells contain only an average of 1-2 CFTR transcripts per cell (21) , it was concluded that, at most, 8-16% bronchial epithelial cells need to express exon9+ CFTR transcripts in order to maintain a normal phenotype (15) . It is known that the relative proportion of exon9+ CFTR transcripts is not different between nasal and bronchial epithelial cells (16) . Based on our findings in nasal epithelial cells, a higher proportion than 8-16% nasal/bronchial epithelial cells, as initially described by Chu et al. (15) , need to express exon9+ CFTR transcripts in order to maintain a normal phenotype. Table 2 . Nature of CFTR transcripts in cultured and fresh nasal epithelial cells
For each sample, the mean proportion of exon9+ and exon9-CFTR transcripts is calculated as the mean of the proportions found for each measurement. Replicate RNA extractions, cDNA and PCR reactions were performed for each sample. 95% confidence intervals of the means are also given. The total number of measurements is indicated by n.
As shown in Table 3 , reverse transcription PCR was then performed on 27 samples of cultured nasal epithelial cells (20 samples were derived from males, seven were derived from females). The mean proportion, and their 95% confidence intervals, of exon9-transcripts for the observed genotypes were: T9/T9, 0.01 ± 0.00; T9/T7, 0.06 ± 0.01; T7/T7, 0.14 ± 0.01; and T7/T5, 0.46 ± 0.03. Analysis of variance revealed that the means from the four groups were significantly different from each other (P < 0.001). Subsequent post-hoc pairwise comparison tests according to Bonferroni showed that the means for all tested genotypes were significantly different from each other (P <0.003).
Qualitative and quantitative CFTR transcript analysis of vas deferens biopsies revealed that alternative splicing of exon 9 also occurred in this tissue. The same inverse relationship between the number of thymidines and the amount of exon9-transcripts was observed as in nasal/bronchial epithelial cells and lymphocytes.
However, for all samples tested, the proportion of exon9-transcripts was increased in vas deferens cells compared with nasal epithelial cells (Fig. 1) . Most vas deferens and nasal biopsies were obtained from individuals homozygous for the T7 allele. Within this most extensively studied group, 24 ± 1% of the CFTR transcripts derived from vas deferens cells lacked exon 9 (Table 1) , while only 14 ± 1% of the CFTR transcripts derived from nasal epithelial cells lacked exon 9 sequences (Table 3) . Also for the three other Tn genotypes studied, although a lower number of individuals were tested within each of these groups, the same trend was observed for all samples tested. For the individual genotypes (T9/T9, T9/T7 and T7/T7), the proportions of exon9-CFTR transcripts found in vas deferens were significantly higher than in nasal epithelial cells (t-test of pooled variances, after correction for multiple testing: P < 0.001). While we cannot exclude the possibility that our findings reflect variability in CFTR expression between individuals, the fact that the same trend is observed in more than 20 samples, regardless of the Tn genotype, strongly suggests that the proportion of exon9-transcripts is increased in vas deferens cells compared with nasal epithelial cells. Importantly, partial data of another study revealed that the proportion of exon9-CFTR transcripts was increased in the epididymis compared with the nasal epithelial cells of two CBAVD individuals (22) . The data of that study, although another urogenital tissue was investigated, and our data therefore complement each other. It is not clear why, and by which mechanism, this proportion is increased: it could be caused by factors at the transcriptional or post-transcriptional level, or both. A possible mechanism at the transcriptional level could be the use of a different splicing machinery in vas deferens cells compared with nasal epithelial cells such that the intron 8 splice acceptor site is used with an even lower efficiency than in nasal epithelial cells. A possible mechanism at the post-transcriptional level could be the presence of factors that reduce the stability of exon9+ transcripts, or increase the stability of exon9-transcripts, or both, in vas deferens cells. For each sample, the mean proportion of exon9+ and exon9-CFTR transcripts is calculated as the mean of the proportions found for each measurement. Replicate RNA extractions, cDNA and PCR reactions were performed for each sample. 95% confidence intervals of the means are also given. The total number of measurements for each sample is indicated by n. a Average proportion of exon9+ and exon9-CFTR transcripts found for a given genotype. All nasal biopsies were obtained from other individuals than those who provided vas deferens biopsies (Table 1) . Underlined samples were derived from female individuals, the others were derived from male individuals. No significant differences were found in the obtained quantitative data whether the samples were of female or male origin: for the T9/T7 genotype, 94 ± 2% of the transcripts contained exon 9 when derived from male individuals and 93 ± 1% of the transcripts contained exon 9 sequences when derived from female individuals; for the T7/T7 genotype, 87 ± 1% of the transcripts contained exon 9 when derived from male individuals and 84 ± 1% of the transcripts contained exon 9 sequences when derived from female individuals.
CBAVD patients have no, or only minor, pulmonary symptoms (9, 12 ). An increased proportion of exon9-transcripts in vas deferens tissue could be relevant to this observation. Indeed, exon9-CFTR transcripts will not produce functional chloride channels (17, 18) . In CBAVD individuals that carry the T5 allele, a normal phenotype will be sustained as long as a sufficient number of normal CFTR proteins is available in the cells. A further decrease in the absolute number of normal CFTR proteins, by further increasing the proportion of exon9-CFTR transcripts, could then result in an abnormal phenotype. But also for other CBAVD mutations (9-11), mainly of the missense type of which the majority will be associated with T7, mild mutant CFTR proteins with partial chloride channel activity (23) could sustain a normal phenotype as long as a sufficient number of such mutant CFTR proteins is available in the cells. Again, a decrease in the absolute number of such mutant CFTR proteins, by increasing the proportion of exon9-transcripts, could result in an abnormal phenotype. The difference in proportion of exon9-transcripts between vas deferens and nasal epithelial cells might therefore be the mechanism, or contribute to the mechanism, which makes a mild CFTR mutation, a disease causing one in vas deferens tissue and not in nasal/bronchial epithelial cells. It is not known, however, if nasal/bronchial and vas deferens epithelial cells require the same threshold of CFTR activity in order to maintain a normal phenotype. It should also be noted that the CFTR transcript analysis was performed in vas deferens cells that were obtained from normal adult men. It is therefore not known if our observation of an increased proportion of exon9-transcripts in the vas deferens also holds true for the embryonic stages, or even for the Wolffian duct from which the vas deferens develops. It will be quite difficult, however, for ethical reasons, to test this in foetal samples, while the absence of exon 9 alternative splicing in animals investigated so far (18) precludes the study in animal models.
As long as the function of CFTR in vas deferens and its role in the pathology of CBAVD is unknown, the importance of our finding of an increased proportion of exon9-transcripts in vas deferens will remain difficult to evaluate.
MATERIALS AND METHODS

Study population
Vas deferens biopsies were obtained from healthy men who underwent a vasectomy for birth control purposes. Nasal biopsies were obtained from other individuals suffering from chronic nasal obstruction or sinusitis. The latter cells were cultured as previously described (24) .
Qualitative and quantitative CFTR transcript analysis
Total RNA was extracted from the different cell types with the TRIzol TM reagent, according to the protocol provided by the manufacturer (Life Technologies, Merelbeke, Belgium). The cDNA synthesis reaction was performed in a 20 µl solution containing 50 mM Tris-HCl (pH8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, 0.5 mM dNTPs; 0.5 µg oligo(dT) [12] [13] [14] [15] [16] [17] [18] (Pharmacia Biotech, Uppsala, Sweden), 2 µg total RNA and 200 U M-MLV reverse transcriptase (Life Technologies, Merelbeke, Belgium). The cDNA synthesis reaction was performed at 37_C for 60 min. CFTR cDNA was quantitatively amplified with primers (5′-GGT ATG ACT CTC TTG GAG CAA-3′ and 5′-FITC-GTG ATT CCA CCT TCT CCA-3′) (Pharmacia Biotech, Uppsala, Sweden) located in exons 7 and 11
[at nucleotide positions 1214 and 1772, respectively, according to the nucleotide number assignment made by Riordan et al. (4) ]. The primers were carefully chosen such that they would not be directed against regions located in exons known to be involved in alternative splicing. One of the amplification primers was FITC labelled such that the sensitive ALF DNA analysis system (Pharmacia Biotech, Uppsala, Sweden) could be used for the detection and quantification of the different signals. PCR amplifications were performed in 50 µl reaction solutions containing 35 mM KCl, 5 mM Tris-HCI (pH 8.3), 1.2 mM MgCl 2 , 0.01% gelatine, 0.15 mM dNTPs, 200 nM of each primer, 1.25 U AmpliTaq DNA polymerase (Perkin Elmer, Gouda, The Netherlands) and 5 µl cDNA synthesis mix. The PCR reactions were performed in a DNA thermal cycler 480 (Perkin Elmer, Gouda, The Netherlands). The temperature cycling conditions were: denaturation for 1 min at 94_C, annealing for 1 min at 62_C and extension for 2 min at 72_C. The first denaturation step was performed for 6 min. For non-quantitative purposes, an extension time of 1 min is used. For quantitative purposes, this extension time was doubled in order to make sure that each template was fully replicated during each cycle. The reproducibility of the quantitative measurements was evaluated by replicate RNA extractions, cDNA synthesis and PCR reactions.
Upon amplification, PCR fragments derived from CFTR transcripts that contain exon 9 sequences will be 559 bp long, those lacking exon 9 will be 376 bp. The PCR samples were denatured through addition of formamide and by incubation at 90_C for 3 min. The fragments were subsequently sized on a 34 × 18 cm 5% Long Ranger TM (J. T. Baker, Phillipsburg, NJ)/7 M urea/1.2× TBE (120 mM Tris, 99.6 mM boric acid, 1.2 mM EDTA) gel on the ALF DNA analysis system using 0.6× TBE (60 mM Tris, 49.8 mM boric acid, 0.6 mM EDTA) as running buffer. Quantification of the different fragments was performed with the ALF fragment manager V1.1 software (Pharmacia Biotech, Uppsala, Sweden). By means of this software, the size of the peaks obtained, and their area, was calculated. The area of each peak for a given sample was then normalized against the sum of the areas of all peaks obtained for that sample. The means of the replicated measurements, and their 95% confidence intervals, were calculated.
In order to check if the amplification was stopped in the exponential phase of the PCR, duplicate PCR reactions, one being performed for two additional PCR cycles, were performed. The latter control was used to check if the different fragments were equally well amplified. Indeed, in the saturation phase of a PCR reaction, smaller fragments could be more efficiently amplified than larger fragments. For each sample, the qualitative and quantitative measurements for the duplicate PCR reactions were not significantly different from each other, showing that the smaller fragments were not more efficiently amplified. Moreover, in the exponential phase of the PCR reaction, the amount of the signals of the PCR sample that was amplified for two additional cycles should be increased by a factor of four, compared with the signals obtained for the PCR sample that was not amplified for an additional two cycles.
All data are presented as mean proportion ± 95% confidence interval of the mean. The data were statistically analysed by means of variance analysis, post-hoc pairwise comparison tests according to Bonferroni, and t-tests of pooled variances.
Genomic analysis
The genotype at the Tn locus of the different samples was determined at the genomic level by means of direct automatic sequencing of exon 9, and its exon/intron junctions, as previously described (25) .
